Orasi Medical Inc. said Danish drugmaker H. Lundbeck A/S will use its software to test experimental drug compounds on the human brain.
Spun out of the University of Minnesota, Orasi has developed technology that can help drug firms determine if their therapies are working by comparing novel brain scans of patients with neurological diseases to its image database of people with normal brain activity.
Orasi says it owns the largest commercial database of magnetoencephalography (MEG) scans and is the only provider of MEG biomarkers, the genetic clues scientists use to identify diseases. Drug companies can determine whether or not to pursue a therapy rather than spend billions on a drug with a high likelihood of failure.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
“By identifying the right drug and dosing early, we will help companies like Lundbeck develop more effective drugs for the many people that are affected by CNS diseases.” Sarah Haecker, Orasi’s vice president of pharmaceutical business development, said in a statement. “Our novel biomarker technology, Orasi Index, can objectively measure if the drug is reaching the brain and what effect the drug is having. It is a huge leap forward for pharmaceutical drug development processes for a multitude of CNS disorders.”
Based in Denmark, Lundbeck is developing drugs to treat neurological disorders like schizophrenia, Alzheimer’s and Parkinson’s diseases. In 2009, the company generated $2.6 billion.
